10-Q: Cell Source Inc. Reports Third Quarter 2024 Results Amidst Financial Challenges

Cell Source Inc. reports a net loss of $4.18 million for the nine months ended September 30, 2024, alongside ongoing efforts to secure additional funding.

Summary

• Cell Source Inc. reported a net loss of $4.18 million for the nine months ended September 30, 2024, compared to a net loss of $4.27 million for the same period in 2023.
• The company's operating expenses totaled $3.16 million for the nine months ended September 30, 2024, a slight decrease from $3.32 million in the prior year.
• Research and development expenses increased to $1.54 million for the nine months ended September 30, 2024, up from $1.22 million in 2023, primarily due to patient enrollment milestones.
• General and administrative expenses decreased to $1.63 million for the nine months ended September 30, 2024, down from $2.10 million in 2023, mainly due to reduced legal and consulting costs.
• The company's cash balance was $22,992 as of September 30, 2024, with a working capital deficiency of approximately $18.94 million and an accumulated deficit of approximately $45.85 million.
• Notes payable with principal amounts totaling approximately $5.66 million were past due as of September 30, 2024, raising concerns about the company's ability to continue as a going concern.
• The company is actively negotiating to raise additional capital through debt and equity financings to fund operations.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including substantial losses, a large working capital deficiency, and past due debt, raising serious concerns about the company's viability. While there are some positive developments in research and development, the overall sentiment is negative due to the company's precarious financial situation.

Positives

• The company has made progress in its research and development efforts, with preclinical data confirming the potential of Veto Cells.
• The Phase 1/2 clinical trial at MD Anderson has shown no toxicity associated with Veto Cells, with patients showing successful stem cell engraftment.
• The company has successfully raised capital through the issuance of Series B Convertible Preferred Stock and common stock.
• The company is actively negotiating with debt holders to extend maturity dates or convert debt into equity.

Negatives

• The company has incurred significant net losses, with a net loss of $4.18 million for the nine months ended September 30, 2024.
• The company has a substantial working capital deficiency of approximately $18.94 million.
• The company has a significant amount of past due notes payable, totaling approximately $5.66 million.
• The company's cash balance is very low at $22,992 as of September 30, 2024.
• The company is operating on a month-to-month basis, indicating financial instability.
• The company has not generated any revenues during the nine months ended September 30, 2024.

Risks

• The company's ability to continue as a going concern is in doubt due to its financial condition.
• The company may have to curtail its development, marketing, and promotional activities if it cannot secure additional financing.
• The company's debt holders may not agree to convert their notes into equity or extend the maturity dates of their notes.
• The company is subject to the risks associated with the ongoing conflict between Israel and Hamas, which could impact its operations.
• The company's reliance on debt and equity financings may not be sufficient to fully complete its development activities or attain profitable operations.

Future Outlook

The company plans to submit a clinical protocol for allogeneic VETO CAR-T HSCT combined therapy for blood cancer treatment for approval in 2025 and is actively negotiating to raise additional capital through debt and equity financings.

Management Comments

• Management's plans include continued efforts to raise additional capital through debt and equity financings.
• Management believes that the estimates and judgments upon which they rely are reasonable based upon information available at the time that they make these estimates and judgments.

Industry Context

The company is operating in the competitive biotechnology sector, focusing on cell therapy and immunotherapy, which are areas of significant interest and investment. The company's Veto Cell technology aims to address key challenges in immune tolerance, which is a critical factor in the success of stem cell and organ transplantation, as well as CAR-T cell therapy. The company's focus on allogeneic CAR-T therapy aligns with the industry's push for more accessible and cost-effective treatments.

Comparison to Industry Standards

• Cell Source's financial results are concerning when compared to industry standards for biotechnology companies at a similar stage of development.
• Many comparable companies in the cell therapy space have secured significant funding through venture capital or strategic partnerships, while Cell Source is relying heavily on debt and small private placements.
• Companies like Kite Pharma (acquired by Gilead), Juno Therapeutics (acquired by Celgene), and bluebird bio have demonstrated the potential for significant revenue generation in the CAR-T space, but they also have substantial financial backing and established clinical pipelines.
• Cell Source's reliance on convertible notes and related party transactions is not typical for companies with advanced clinical programs, and this may raise concerns about corporate governance and financial stability.
• The company's low cash balance and significant debt obligations are not in line with industry benchmarks for companies pursuing clinical trials and commercialization.

Legal Proceedings

• In January 2019, a collection action was instituted against the company regarding a promissory note, which was resolved in June 2024 with a final payment of $135,000.

Related Party Transactions

• The company has convertible notes payable to related parties, including a director of the company.
• The company has received advances from related parties for working capital purposes.
• The company has accrued interest and warrant obligations to former directors in connection with loans made to the company.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential for dilution.
• Employees and consultants may be impacted by potential curtailment of operations if the company cannot secure additional funding.
• Creditors face the risk of non-payment due to the company's past due debt obligations.
• Patients participating in clinical trials may be affected by potential delays or disruptions in the company's research and development activities.

Next Steps

• The company plans to submit a clinical protocol for allogeneic VETO CAR-T HSCT combined therapy for blood cancer treatment for approval in 2025.
• The company will continue to negotiate with debt holders to extend maturity dates or convert debt into equity.
• The company will continue to seek additional capital through debt and equity financings.

Key Dates

Keywords

cell therapy, immunotherapy, Veto Cell technology, stem cell transplantation, CAR-T therapy, biotechnology, clinical trials, financial results, going concern, debt financing, equity financing